Article Text

PDF

Correspondence response
Response to: ‘Drugs and cardiovascular risk in inflammatory arthritis: another case of glucocorticoid-bashing?’ by Dr Boers
  1. Camille Roubille1,
  2. Vincent Richer2,
  3. Tara Starnino3,
  4. Collette McCourt4,
  5. Alexandra McFarlane5,
  6. Patrick Fleming6,
  7. Stephanie Siu7,
  8. John Kraft8,
  9. Charles Lynde8,
  10. Janet Pope7,
  11. Wayne Gulliver9,
  12. Stephanie Keeling5,
  13. Jan Dutz4,
  14. Louis Bessette10,
  15. Robert Bissonnette11,
  16. Boulos Haraoui12
  1. 1University of Montreal Hospital Research Center (CRCHUM), Montreal, Quebec, Canada
  2. 2Department of Medicine, Dermatology Service, St-Luc Hospital, Montreal, Quebec, Canada
  3. 3Sacré-Coeur Hospital of Montreal, University of Montreal, Montreal, Quebec, Canada
  4. 4Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada
  5. 5Division of Rheumatology, University of Alberta, Edmonton, Alberta, Canada
  6. 6Division of Dermatology, University of Toronto, Toronto, Ontario, Canada
  7. 7Division of Rheumatology, Department of Medicine, Western University of Canada, St. Joseph's Health Care, London, Ontario, Canada
  8. 8Lynde Dermatology, Markham, Ontario, Canada
  9. 9Faculty of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada
  10. 10Department of Medicine, Centre de Recherche du CHU de Québec, Laval University, Quebec City, Quebec, Canada
  11. 11Innovaderm Research, Montreal, Quebec, Canada
  12. 12Department of Medicine, Rheumatic Disease Unit, Centre Hospitalier de l'Université de Montréal (CHUM) and Institut de Rhumatologie de Montréal, Montreal, Quebec, Canada
  1. Correspondence to Dr Boulos Haraoui, Institut de Rhumatologie de Montreal, 1551 Ontario Street East, Montreal, Quebec, Canada H2L 1S6; boulos.haraoui{at}ssss.gouv.qc.ca

Statistics from Altmetric.com

We thank Dr Boers for the interesting comments1 on our paper2. First, the decision to exclude studies reporting less than 400 patients was made after noticing that most of these studies had less than 1 year of follow-up or had large drop-outs with few remaining patients at or beyond 1 year. We also reviewed the abstract by Tarp et al.3 Among a total of 4831 subjects, 1944 were specifically analysed for cardiovascular purpose; no statistically significant increase in cardiovascular diseases was found in subjects treated with glucocorticoids. Of note, given that this is an abstract, we had no precise data regarding inclusion and exclusion criteria, as well as references of the included randomised controlled trials. Some lack of statistical power may be hypothesised because of low sample size. Our meta-analysis exploring the association between the use of glucocorticoids and cardiovascular events, analysed a total of 83 205 subjects included in 11 observational studies. Importantly, the median study duration of 24 weeks, may not be sufficient to report cardiovascular events, and to ensure that the impact of glucocorticoids was a true effect and not due to chance in a short duration of observation. Second, we agree with Dr Boers that observational studies may suffer from some channelling biases, but specifically regarding glucocorticoids the evidence is so overwhelming for all the outcomes studied pointing in the same direction, that it would be difficult to speculate that unaccounted confounding factors could have altered the data in a significant manner. Finally, the purpose of this review was not to balance cardiovascular effects of the studied drugs against their potential benefits, and definitely not to specifically bash glucocorticoids since we did not address other potential side effects. In one of our meta-analyses on the effects of bone density in RA and seronegative arthritis, we found that in rheumatoid arthritis (RA), glucocorticoids improved bone mass in the wrist (likely due to decreasing inflammation) but worsened bone mass elsewhere.4 However, we should be reminded that it is now part of all recommendations including the European League Against Rheumatism, to limit the use of glucocorticoids to the lowest dose and for the shortest duration possible.

References

View Abstract

Footnotes

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles